Novavax COVID-19 vaccine is 89 percent effective, but much less so against South African strain
Novavax, a biotech firm based in Maryland, announced Thursday that its COVID-19 vaccine was 89.3 percent effective at protecting people from the disease in Britain, including against a new and more infectious strain now dominant in the U.K., but only 49 percent effective in a smaller trial in South Africa. More than 90 percent of the South African subjects who got sick were infected with the new strain, according to preliminary results. Novavax announced the interim results of its Phase 3 U.K. study and Phase 2 trial in South Africa in a press release.
Novavax's findings were a sobering signal that the current vaccines won't work as well against the new variants. The company's vaccine appeared to be 95.6 percent effective against the original strain of the coronavirus but 85.6 percent effective against the U.K. variant. Novavax also said its vaccine was 60 percent effective in its South African trial if you excluded the subgroup with HIV. It is already working on a modified version of its vaccine to specifically target the South African variant, which was first confirmed have hit the U.S. on Thursday.
The U.S. has approved COVID-19 vaccines from Pfizer/BioNTech and Moderna, and Johnson & Johnson is expected to release the findings of its Phase 3 trial sometime next week. Johnson & Johnson has been testing its vaccine in South Africa and Brazil, home to another new mutation, so health experts are hoping to get more clues about how current vaccines fare against the new strains.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Novavax said it has already started the process to seek regulatory approval for its vaccine in the U.K., and it could be approved in the U.S. as early as April, though the Food and Drug Administration might wait for the results of its ongoing Phase 3 trial in Mexico and the U.S. Public health officials would welcome any new supply of a safe and effective vaccine. The FDA has said vaccine candidates have to be at least 50 percent effective. The U.S. contributed $1.6 billion to Novavax's vaccine effort last year and has preordered 100 million doses.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
4 ways to give back this holiday season
The Explainer If your budget is feeling squeezed, remember that money is not the only way you can be generous around the holidays
By Becca Stanek, The Week US Published
-
4 tips for hosting an ecofriendly Thanksgiving
The Week Recommends Coming together for the holidays typically produces a ton of waste, but with proper preparation, you can have an environmentally friendly gathering.
By Theara Coleman, The Week US Published
-
Jussie Smollet conviction overturned on appeal
Speed Read The Illinois Supreme Court overturned the actor's conviction on charges of staging a racist and homophobic attack against himself in 2019
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published